Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment

Fig. 1

Alleviating tumor hypoxia by atovaquone via inhibiting mitochondrial complex activity of tumor cells. a, b OCR trace of MC38 cells (15,000 cells/well) interrogated for mitochondrial activity in the Seahorse instrument. c APC-Hypoxia probe staining of tumor sections from mice bearing MC38 tumors receiving PBS or atovaquone treatment for 7 days. Scale bar: 200 μm. Data are presented as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us